These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35652548)

  • 21. Relationship between changes in prostate-specific antigen and the percent of prostatic epithelium in men with benign prostatic hyperplasia.
    Cadeddu JA; Pearson JD; Lee BR; Landis P; Partin AW; Epstein JI; Carter HB
    Urology; 1995 May; 45(5):795-800. PubMed ID: 7538241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of 5α-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix®) vaporesection for treating benign prostatic hyperplasia.
    Chung JS; Seo WI; Oh CK; Kim SC; Park MC; Park SH; Yu J; Lee CH; Kim W; Park TY; Min KS; Chung JI
    Investig Clin Urol; 2020 Jan; 61(1):67-74. PubMed ID: 31942465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
    Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
    Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia.
    Choi JD; Yoo TK; Kang JY; Jung HD; Lee JH
    Int Urol Nephrol; 2023 Apr; 55(4):845-851. PubMed ID: 36763223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interactions between benign prostatic hyperplasia (BPH) and prostate cancer in large prostates: a retrospective data review.
    Al-Khalil S; Boothe D; Durdin T; Sunkara S; Watkins P; Yang S; Haynes A; de Riese W
    Int Urol Nephrol; 2016 Jan; 48(1):91-7. PubMed ID: 26590832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medications and surgical interventions for benign prostatic hyperplasia are potential confounders of prostate-specific antigen.
    Modi P; Helfand BT; McVary KT
    Curr Urol Rep; 2010 Jul; 11(4):224-7. PubMed ID: 20467844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    Jhang JF; Jiang YH; Kuo HC
    Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
    Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
    Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High serum prostate-specific antigen levels in the absence of prostate cancer in Middle-Eastern men: the clinician's dilemma.
    Kehinde EO; Sheikh M; Mojimoniyi OA; Francis I; Anim JT; Nkansa-Dwamena D; Al-Awadi KA
    BJU Int; 2003 May; 91(7):618-22. PubMed ID: 12699471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
    Chung BH; Hong SJ; Cho JS; Seong DH
    BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of patients with diseases of the prostate using prostate-specific antigen density.
    Wolff JM; Boeckmann W; Effert PJ; Handt S; Jakse G
    Br J Urol; 1995 Jul; 76(1):41-6. PubMed ID: 7544203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Five-alpha reductase inhibitors and risk of prostate cancer among men with benign prostatic hyperplasia: A historical cohort study using primary care data.
    Thakrar DB; Douglas IJ; Smeeth L; Bhaskaran K
    Wellcome Open Res; 2023; 8():295. PubMed ID: 38774490
    [No Abstract]   [Full Text] [Related]  

  • 34. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
    Stephan C; Lein M; Jung K; Schnorr D; Loening SA
    Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy.
    Heo JE; Koo KC; Hong SJ; Park SU; Chung BH; Lee KS
    Yonsei Med J; 2018 Mar; 59(2):219-225. PubMed ID: 29436189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Racial differences in cellular composition of benign prostatic hyperplasia.
    Aoki Y; Arai Y; Maeda H; Okubo K; Shinohara K
    Prostate; 2001 Dec; 49(4):243-50. PubMed ID: 11746270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Correlation of serum prostate specific antigen, the volume and the intravesical prostatic protrusion for diagnosing bladder outlet obstruction in patients with benign prostate hyperplasia].
    Bantis A; Zissimopoulos A; Kalaytzis C; Giannakopoulos S; Sountoulides P; Agelonidou E; Voudalikakis C; Touloupidis S
    Hell J Nucl Med; 2007; 10(2):138-43. PubMed ID: 17684595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario.
    Prestigiacomo AF; Lilja H; Pettersson K; Wolfert RL; Stamey TA
    J Urol; 1996 Aug; 156(2 Pt 1):350-4. PubMed ID: 8683677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.